AR098908A1 - Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida - Google Patents

Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida

Info

Publication number
AR098908A1
AR098908A1 ARP140104850A ARP140104850A AR098908A1 AR 098908 A1 AR098908 A1 AR 098908A1 AR P140104850 A ARP140104850 A AR P140104850A AR P140104850 A ARP140104850 A AR P140104850A AR 098908 A1 AR098908 A1 AR 098908A1
Authority
AR
Argentina
Prior art keywords
methyl
hidroxifenil
octahidro
pirazino
bencil
Prior art date
Application number
ARP140104850A
Other languages
English (en)
Inventor
Inoue Satoshi
Yamamoto Yuji
Original Assignee
Eisai R&D Man Co Ltd
Prism Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Prism Pharma Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR098908A1 publication Critical patent/AR098908A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

Un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable de este: donde R¹ es un grupo alquilo C₁₋₆; R² y R³ son iguales o diferentes entre sí y cada uno es un átomo de hidrógeno o un grupo alquilo C₁₋₆; X², X³ y X⁴ son iguales o diferentes entre sí y cada uno es un átomo de hidrógeno o un átomo de halógeno; y X⁵ es un átomo de hidrógeno o -P(=O)(OH)₂, tiene una actividad de modulación de vía Wnt.
ARP140104850A 2013-12-25 2014-12-22 Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida AR098908A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013267687 2013-12-25

Publications (1)

Publication Number Publication Date
AR098908A1 true AR098908A1 (es) 2016-06-22

Family

ID=53399298

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104850A AR098908A1 (es) 2013-12-25 2014-12-22 Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida

Country Status (34)

Country Link
US (1) US9174998B2 (es)
EP (1) EP3088401B1 (es)
JP (1) JP6085040B2 (es)
KR (1) KR102307053B1 (es)
CN (1) CN105873932B (es)
AR (1) AR098908A1 (es)
AU (1) AU2014371148B2 (es)
BR (1) BR112016013572B1 (es)
CA (1) CA2932435C (es)
CL (1) CL2016001419A1 (es)
CY (1) CY1122521T1 (es)
DK (1) DK3088401T3 (es)
ES (1) ES2728353T3 (es)
HK (1) HK1222656A1 (es)
HR (1) HRP20190908T1 (es)
HU (1) HUE044541T2 (es)
IL (1) IL245961A0 (es)
JO (1) JO3809B1 (es)
LT (1) LT3088401T (es)
ME (1) ME03391B (es)
MX (1) MX365376B (es)
MY (1) MY173946A (es)
PE (1) PE20160932A1 (es)
PH (1) PH12016501079A1 (es)
PL (1) PL3088401T3 (es)
PT (1) PT3088401T (es)
RS (1) RS58955B1 (es)
RU (1) RU2669805C2 (es)
SG (1) SG11201604496YA (es)
SI (1) SI3088401T1 (es)
TR (1) TR201908392T4 (es)
TW (1) TWI681961B (es)
UA (1) UA116923C2 (es)
WO (1) WO2015098853A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) * 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
SG11201709593VA (en) * 2015-06-23 2017-12-28 Eisai R&D Man Co Ltd CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
CN108084067B (zh) * 2016-11-22 2019-08-30 重庆圣华曦药业股份有限公司 一种立他司特中间体的制备方法
US20190388420A1 (en) * 2017-02-08 2019-12-26 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
KR20220092540A (ko) 2019-10-29 2022-07-01 에자이 알앤드디 매니지먼트 가부시키가이샤 암을 치료하기 위한 pd-1 길항제, vegfr/fgfr/ret 티로신 키나제 억제제 및 cbp/베타-카테닌 억제제의 조합물
MX2022011257A (es) 2020-03-12 2023-01-11 3 2 Pharma Llc Inhibidores de la vía de señalización de cbp/catenina y usos de los mismos.
US20230390296A1 (en) 2020-10-30 2023-12-07 Keio University Novel treatment and prevention of sarcopenia-related diseases
WO2023027888A1 (en) * 2021-08-26 2023-03-02 3+2 Pharma, Llc Pyrazole-containing cbp/catenin antagonists and uses thereof
CN117794544A (zh) 2021-09-08 2024-03-29 卫材R&D管理有限公司 实体瘤治疗用医药组合物
WO2023140369A1 (en) * 2022-01-18 2023-07-27 Prism BioLab Co., Ltd. Phosphoric acid derivatives
WO2023190748A1 (ja) * 2022-03-31 2023-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
CN115784934A (zh) * 2022-11-22 2023-03-14 上海吉奉生物科技有限公司 一种酪氨酸衍生物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100910307B1 (ko) * 2001-10-12 2009-08-03 주식회사 중외제약 리버스-턴 유사체 및 이와 관련된 방법
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
BRPI0911383B1 (pt) * 2008-06-06 2021-08-31 Prism Biolab Corporation Composto, composição farmacêutica, uso do referido composto, agentes para tratar ou prevenir câncer, fibrose, restenose associada com angioplastia, doença renal policística, doença de angiogênese aberrante, complexo de esclerose tuberosa (tsc) tumor associado com kshv, perda de cabelo, e doença de alzheimer, e processo para preparar o referido composto
US20100267672A1 (en) * 2009-04-15 2010-10-21 Choongwae Pharma Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
JP5809279B2 (ja) 2010-10-14 2015-11-10 ジェイダブリュ ファーマセウティカル コーポレーション リバースターン類似体の新規な化合物およびその製造方法と用途
CN103517904A (zh) * 2011-02-25 2014-01-15 株式会社棱镜制药 α-螺旋模拟物和与其相关的方法

Also Published As

Publication number Publication date
SI3088401T1 (sl) 2019-08-30
BR112016013572B1 (pt) 2023-03-21
PH12016501079A1 (en) 2016-07-11
PL3088401T3 (pl) 2019-09-30
ES2728353T3 (es) 2019-10-23
UA116923C2 (uk) 2018-05-25
IL245961A0 (en) 2016-08-02
CA2932435A1 (en) 2015-07-02
JP6085040B2 (ja) 2017-02-22
US9174998B2 (en) 2015-11-03
CL2016001419A1 (es) 2017-01-20
ME03391B (me) 2020-01-20
EP3088401A1 (en) 2016-11-02
WO2015098853A1 (ja) 2015-07-02
HUE044541T2 (hu) 2019-10-28
JPWO2015098853A1 (ja) 2017-03-23
US20150175615A1 (en) 2015-06-25
BR112016013572A2 (es) 2017-10-03
TR201908392T4 (tr) 2019-07-22
MX365376B (es) 2019-05-31
EP3088401A4 (en) 2017-06-28
NZ720718A (en) 2020-10-30
MX2016007705A (es) 2017-01-11
JO3809B1 (ar) 2021-01-31
KR20160094980A (ko) 2016-08-10
CN105873932B (zh) 2017-11-24
KR102307053B1 (ko) 2021-10-01
CY1122521T1 (el) 2021-01-27
AU2014371148B2 (en) 2018-08-09
PE20160932A1 (es) 2016-09-10
HK1222656A1 (zh) 2017-07-07
AU2014371148A1 (en) 2016-06-23
RU2669805C2 (ru) 2018-10-16
PT3088401T (pt) 2019-06-12
TWI681961B (zh) 2020-01-11
DK3088401T3 (da) 2019-06-03
SG11201604496YA (en) 2016-07-28
HRP20190908T1 (hr) 2019-08-09
LT3088401T (lt) 2019-07-25
CN105873932A (zh) 2016-08-17
CA2932435C (en) 2021-08-17
RS58955B1 (sr) 2019-08-30
RU2016122867A3 (es) 2018-06-18
RU2016122867A (ru) 2018-02-01
MY173946A (en) 2020-02-28
EP3088401B1 (en) 2019-03-06
TW201609736A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
AR098908A1 (es) Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida
PE20151606A1 (es) DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA
UA113643C2 (xx) N-цикліламіди як нематоциди
EA201591457A1 (ru) Терапевтические соединения
AR089623A1 (es) Inhibidores de iap
NZ703040A (en) Macrocyclic inhibitors of flaviviridae viruses
EA201600091A1 (ru) 4-членные кольцевые карбоксамиды, применяемые в качестве нематоцидов
NZ703062A (en) Macrocyclic inhibitors of flaviviridae viruses
AR093767A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos
MX2015012629A (es) Compuestos de imidazo piridina.
RS54730B1 (sr) Inhibitori beta sekretaze
CR20130539A (es) Triazolopiridinas
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR097866A1 (es) Derivados de 4-azaindol
JP2015518492A5 (es)
JP2014521346A5 (es)
AR095523A1 (es) Derivados piridin-4-ilo
AR091770A1 (es) Indolcarbonitrilos moduladores selectivos de receptores androgenicos
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
AR101222A1 (es) Derivados de piridona
AR098215A1 (es) Compuesto heterocíclico
DK3725810T3 (da) Kombinationterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
CO6670582A2 (es) Compuesto de piridina sustituida que tiene actividad de inhibición de cetp
AR101588A1 (es) Compuesto tetrahidroimidazo[1,5-d][1,4]oxazepínico

Legal Events

Date Code Title Description
FG Grant, registration